BR112014021331B1 - Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses - Google Patents

Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses Download PDF

Info

Publication number
BR112014021331B1
BR112014021331B1 BR112014021331-3A BR112014021331A BR112014021331B1 BR 112014021331 B1 BR112014021331 B1 BR 112014021331B1 BR 112014021331 A BR112014021331 A BR 112014021331A BR 112014021331 B1 BR112014021331 B1 BR 112014021331B1
Authority
BR
Brazil
Prior art keywords
trifluoromethyl
benzyl
amino
pyrimidine
fluoro
Prior art date
Application number
BR112014021331-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014021331A2 (cg-RX-API-DMAC7.html
BR112014021331A8 (pt
Inventor
Seon-Mi Kim
Jae-Sun Kim
Minhee Lee
So-Young Lee
Bong-Yong Lee
Young Ah Shin
Euisun PARK
Jung A Lee
Min-Young Han
Jaeseung AHN
Taekyung Yoo
Hun-Taek Kim
Original Assignee
Tiumbio Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiumbio Co., Ltd filed Critical Tiumbio Co., Ltd
Publication of BR112014021331A2 publication Critical patent/BR112014021331A2/pt
Publication of BR112014021331A8 publication Critical patent/BR112014021331A8/pt
Publication of BR112014021331B1 publication Critical patent/BR112014021331B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
BR112014021331-3A 2012-02-28 2013-02-28 Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses BR112014021331B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0020479 2012-02-28
KR20120020479 2012-02-28
PCT/KR2013/001660 WO2013129879A1 (en) 2012-02-28 2013-02-28 Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Publications (3)

Publication Number Publication Date
BR112014021331A2 BR112014021331A2 (cg-RX-API-DMAC7.html) 2017-06-20
BR112014021331A8 BR112014021331A8 (pt) 2017-10-10
BR112014021331B1 true BR112014021331B1 (pt) 2020-12-15

Family

ID=49082998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021331-3A BR112014021331B1 (pt) 2012-02-28 2013-02-28 Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses

Country Status (11)

Country Link
US (1) US9481684B2 (cg-RX-API-DMAC7.html)
EP (1) EP2820021B1 (cg-RX-API-DMAC7.html)
JP (1) JP6209171B2 (cg-RX-API-DMAC7.html)
KR (1) KR101495260B1 (cg-RX-API-DMAC7.html)
CN (2) CN104136441B (cg-RX-API-DMAC7.html)
AU (1) AU2013226661B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021331B1 (cg-RX-API-DMAC7.html)
CA (1) CA2865547C (cg-RX-API-DMAC7.html)
ES (1) ES2613856T3 (cg-RX-API-DMAC7.html)
MX (1) MX357841B (cg-RX-API-DMAC7.html)
WO (1) WO2013129879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2674977C2 (ru) 2013-10-30 2018-12-14 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
AU2018305633B2 (en) * 2017-07-28 2022-11-24 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative
KR101973074B1 (ko) 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
CN109651265A (zh) * 2019-02-16 2019-04-19 安徽诺全药业有限公司 一种Elagolix的制备方法
CN112955181B (zh) 2019-03-26 2024-08-13 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115124545B (zh) * 2022-08-31 2023-01-03 南京远淑医药科技有限公司 一种促性腺激素释放激素受体拮抗剂中间体的合成方法
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물
KR20250160081A (ko) * 2024-05-03 2025-11-11 주식회사 티움바이오 에스트로겐-의존성 질환 치료 또는 예방용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163325A1 (en) * 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
US6156772A (en) * 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
MXPA02003614A (es) * 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
EP1412363A1 (en) * 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
JP2005538064A (ja) * 2002-06-13 2005-12-15 ファイザー・インク 非ペプチドGnRH剤、医薬組成物、およびそれらの使用方法
KR20080041662A (ko) * 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
JP5757956B2 (ja) * 2009-11-20 2015-08-05 エスケー ケミカルス シーオー., エルティーディー.Sk Chemicals Co., Ltd. ゴナドトロピン放出ホルモン受容体拮抗剤、その製造方法及びそれを含む医薬組成物

Also Published As

Publication number Publication date
AU2013226661A1 (en) 2014-10-16
CN104136441A (zh) 2014-11-05
JP2015510868A (ja) 2015-04-13
US9481684B2 (en) 2016-11-01
CN104136441B (zh) 2016-09-28
CN105732649A (zh) 2016-07-06
EP2820021A1 (en) 2015-01-07
BR112014021331A2 (cg-RX-API-DMAC7.html) 2017-06-20
ES2613856T3 (es) 2017-05-26
EP2820021A4 (en) 2015-10-21
US20150166558A1 (en) 2015-06-18
CN105732649B (zh) 2019-02-05
BR112014021331A8 (pt) 2017-10-10
EP2820021B1 (en) 2016-11-30
CA2865547A1 (en) 2013-09-06
JP6209171B2 (ja) 2017-10-04
AU2013226661B2 (en) 2017-08-31
CA2865547C (en) 2020-03-10
KR101495260B1 (ko) 2015-02-26
MX357841B (es) 2018-07-26
WO2013129879A1 (en) 2013-09-06
MX2014010345A (es) 2014-11-14
KR20130102002A (ko) 2013-09-16

Similar Documents

Publication Publication Date Title
JP6209171B2 (ja) ゴナドトロピン放出ホルモン受容体アンタゴニスト、その製造方法および該アンタゴニストを含む医薬組成物
CN114040911B (zh) 作为nav1.8抑制剂的2,3-二氢喹唑啉化合物
ES2809974T3 (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas
WO2025078984A1 (en) Substituted tricyclic compounds as kras degraders
CN110963994A (zh) 异吲哚啉类化合物、其制备方法、药物组合物及用途
KR20120060867A (ko) 야누스 키나제 억제제로서의 헤테로시클릭 화합물
CN106414408A (zh) 缩合环吗啡喃和其用途
CN111925379B (zh) 含氮杂芳基取代的嘧啶二酮类化合物及其用途
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
ES2613644T3 (es) Tetrahidroquinolinas condensadas con cicloalquilo como moduladores del receptor CRTH2
KR20150130426A (ko) Ship1 조절제 및 그와 관련된 방법
JP2019514951A (ja) 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体
JP2025508449A (ja) Yap/tazとteadとの相互作用の阻害剤、その製造、医薬組成物及び使用
JP2002544278A (ja) 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストとしてのイミダゾおよびピロロ[1,2−a]ピリミド−4−オン
TW202411233A (zh) 用於治療trpm3介導病症之新型衍生物
JP2002504088A (ja) ベンゾピラノピロール及びベンゾピラノピリジンアルファ−1アドレナリン作用性化合物
KR102756573B1 (ko) mGlu5 수용체의 조절제로서 트리아졸, 이미다졸 및 피롤 축합된 피페라진 유도체 및 이의 용도
JP2007508301A (ja) 脂質代謝異常の治療ための化合物及び方法
CN120641402A (zh) 杂环化合物和其用途
WO2025261355A1 (en) Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
EA053069B1 (ru) Модуляторы gpr35 и их применение
TW202440084A (zh) 作為trpa1抑制劑之雙環醯亞胺化合物
TW202334097A (zh) 用於治療癌症之苯并【h】喹唑啉-4-胺衍生物
KR20250004711A (ko) Gpr35 조절제 및 이의 용도
CN118541354A (zh) 用于治疗癌症的苯并[h]喹唑啉-4-胺衍生物

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TIUMBIO CO., LTD (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2013, OBSERVADAS AS CONDICOES LEGAIS.